Avacincaptad pegol sodium  (Synonyms: ARC1905)

Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system. Avacincaptad pegol sodium treats Geographic atrophy (GA) mice^[1][2][3][4].

Avacincaptad pegol sodium has improvement effects on NaIO₃-induced Geographic atrophy (GA) mice, but the improvement effect is lower than that of IAR045-001^[2].
Avacincaptad pegol sodium is delivered by PEGylated RNA to treat geographic atrophy in macular degeneration^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

53500 (Approximately)

1491144-00-3

Solid

White to off-white

Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, 5′-ether with RNA ((2′-deoxy-2′-fluoro)C-Gm-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-G-(2′-deoxy-2′-fluoro)C-Gm-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-Am-Gm-Gm-(2′-deoxy-2′-fluoro)C-G-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-Am-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-Am-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-A-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)C-Gm-(3′→3′)-dT) 5′-[6-[[(2,3-dihydroxypropoxy)carbonyl]amino]hexyl hydrogen phosphate], sodium salt (2:1:39)

[Avacincaptad pegol sodium]

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Joshua Ong, et al. The Complement System as a Therapeutic Target in Retinal Disease. Medicina (Kaunas). 2024 Jun 5;60(6):945.  [Content Brief]

  [2]. Yiming Li, et al. Targeting both C5 and HTRA1 provides additional rescue effect in NaIO3-induce GA model. IOVS. June 2024, Vol.65, OD68.

  [3]. Aira Sarkar, et al. Novel and investigational therapies for wet and dry age-related macular degeneration. Drug Discov Today. 2022 Aug;27(8):2322-2332.  [Content Brief]

  [4]. Padma Sundaram, et al. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci. 2013 Jan 23;48(1-2):259-71.  [Content Brief]

  [5]. Thomas Ryan Jarrett, et al. Material Trends and Clinical Costings in Systematically Identified CDER-Approved Nanomedicines. Advanced Therapeutics. 02 September 2024.